Neurocrine Biosciences (NBIX) SEC Filings: History & Chart

Neurocrine Biosciences, Inc.(NBIX)

Biotechnology · San Diego, CA

$145.51+1.30 (+0.90%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

San Diego, CA

2,500 employees

www.neurocrine.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kyle W. Gano

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 28, 2026	Sep 28, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 15, 2026	Sep 15, 2026	View filing
4	Sep 10, 2026	Sep 10, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
S-8	Jul 31, 2026	Jul 31, 2026	View filing
8-K/A	Jul 31, 2026	Jul 31, 2026	View filing
10-Q	Jul 31, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 4, 2026	Jun 4, 2026	View filing
4	Jun 4, 2026	Jun 4, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing

SEC Filings

Recent Filings